Scientists have taken a significant step toward developing an effective vaccine against shigellosis, the infection caused by Shigella bacteria. In…
Read More
Johnson & Johnson’s Spravato Remission Data Takes Center Stage in Push for Treatment-Resistant Depression Growth
A recent poster presentation at Psych Congress Elevate by Johnson & Johnson has placed esketamine nasal spray, marketed as Spravato,…
Read More
J&J Positions Spravato Remission Data at Forefront of Treatment-Resistant Depression Growth Strategy
Johnson & Johnson (J&J) is intensifying its marketing efforts for Spravato (esketamine) by spotlighting compelling remission rate data for treatment-resistant…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in 1962 while diligently searching for a safer…
Read More
AI-Driven Breakthrough Uncovers Novel Antibiotics to Combat the Global Threat of Drug-Resistant Gonorrhea
A groundbreaking study led by researchers from the Wyss Institute at Harvard University, MIT, and the Broad Institute of MIT…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in a quest for a safer anesthetic, the…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
Johnson & Johnson is intensifying its efforts to expand the market footprint of Spravato (esketamine) for treatment-resistant depression (TRD), leveraging…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis while searching for a safer anesthetic, the molecule…
Read More
European Commission Approves Keytruda Combination Therapy for PD-L1-Positive Platinum-Resistant Ovarian Cancer
The European Commission (EC) has granted approval for Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, as a…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
For decades, successive waves of antidepressants have promised relief to millions suffering from mood disorders, yet the landscape for those…
Read MoreYOU MAY HAVE MISSED
